Expert opinion on the clinical approach of using sodium glucose cotransporter-2 inhibitors for managing diabetic patients with cardiovascular and renal complications in Indian settings

Simple item page
dc.contributor.authorManjula, Sen_US
dc.contributor.authorKrishna, Kumar Men_US
dc.date.accessioned2024-09-24T08:09:51Z
dc.date.available2024-09-24T08:09:51Z
dc.date.issued2024-02
dc.description.abstractObjective:To evaluate the prescription practice of sodium-glucose co-transporter -2 (SGLT2) inhibitors with a special focus on dapagliflozin to treat cardiac and renal disorders in obese Indian diabetic patients.Methods: A cross-sectional, questionnaire-based study was conducted to collect the perspectives of physicians with expertise in treating diabetic obese patients with cardiac and renal disorders in endocrinology across India between June 2022 and December 2022. Descriptive statistics were used to summarize the characteristics of the study by employing frequencies and percentages.Results:Among the 1,446 survey participants, 80% of them indicated that young diabetic patients with obesity, and obese patients with cardio-renal complications may require SGLT2 inhibitors.Furthermore, patients aged between 41-50 and 51-60 years also required SGLT2 inhibitors for diabetes management accord ing to 57% and 27% of the respondents.The majority of the respondents (91.29% and 90.53%) recommended dapagliflozin as the best SGLT2 inhibitor for treating patients with chronic kidney disease and heart failure.Additionally , about 59% and 66% of the experts indicated that patients would experience an average weight loss of 2-3 kilograms and an average blood pressure reduction of 3-6 mm Hg after 12 weeks of treatment with dapagliflozin, respectively.Conclusion:Experts recommend the use of SGLT2 inhibitors for the treatment of young diabetic patients with obesity and obese subjects with cardiorenal complications.Dapagliflozin monotherapy was preferred for patients with chronic kidney disease and heart failure. Furthermore, experts highly recommend the combinations of dapagliflozin + metformin and DPP4 inhibitors + metformin + dapagliflozin for effective diabetes management.en_US
dc.identifier.affiliationsManjula S, Sr Vice President, Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India.en_US
dc.identifier.affiliationsKrishna Kumar M, Sr General Manager, Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India.en_US
dc.identifier.citationManjula S, Krishna Kumar M. Expert opinion on the clinical approach of using sodium glucose cotransporter-2 inhibitors for managing diabetic patients with cardiovascular and renal complications in Indian settings. International Journal of Medical Research & Review . 2024 Jan; 12(1): 22-28en_US
dc.identifier.issn2320-8686
dc.identifier.issn2321-127X
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/231053
dc.languageenen_US
dc.publisherSiddharth Health Research and Social Welfare Societyen_US
dc.relation.issuenumber1en_US
dc.relation.volume12en_US
dc.source.urihttps://doi.org/10.17511/ijmrr.2024.i01.03en_US
dc.subjectChronic kidney diseaseen_US
dc.subjectDiabetesen_US
dc.subjectDapagliflozinen_US
dc.subjectHeart failuren_US
dc.subjectObesityen_US
dc.titleExpert opinion on the clinical approach of using sodium glucose cotransporter-2 inhibitors for managing diabetic patients with cardiovascular and renal complications in Indian settingsen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijmrr2024v12n1p22.pdf
Size:
716.19 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Medical Research & Review